Literature DB >> 6583717

Relatives of unipolar and bipolar patients have normal pursuit.

D L Levy, N J Yasillo, E Dorus, R Shaughnessy, R D Gibbons, J Peterson, P G Janicak, M Gaviria, J M Davis.   

Abstract

Impaired smooth pursuit eye movements are significantly less prevalent among the first-degree relatives of patients who have major affective disorders than among the first-degree relatives of schizophrenics. The distribution of normal and abnormal smooth pursuit among the relatives of unipolar and bipolar patients does not differ from that of normal individuals having no family history of major psychosis. Smooth pursuit impairment is thus specific to relatives of schizophrenic patients and is not characteristic of relatives of patients with major affective disorders.

Entities:  

Mesh:

Year:  1983        PMID: 6583717     DOI: 10.1016/0165-1781(83)90075-6

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  5 in total

Review 1.  The use of eye movement dysfunctions in exploring the genetic transmission of schizophrenia.

Authors:  P S Holzman
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

2.  Bipolar and schizophrenic patients differ in patterns of visual motion discrimination.

Authors:  Yue Chen; Deborah L Levy; Summer Sheremata; Philip S Holzman
Journal:  Schizophr Res       Date:  2006-07-17       Impact factor: 4.939

3.  Trait vs. State Markers for Schizophrenia: Identification and Characterization through Visual Processes.

Authors:  Yue Chen; L Cinnamon Bidwell; Daniel Norton
Journal:  Curr Psychiatry Rev       Date:  2006-11

Review 4.  Neurophysiological endophenotypes across bipolar and schizophrenia psychosis.

Authors:  Gunvant K Thaker
Journal:  Schizophr Bull       Date:  2008-05-22       Impact factor: 9.306

Review 5.  Saccadic eye movement applications for psychiatric disorders.

Authors:  Juliana Bittencourt; Bruna Velasques; Silmar Teixeira; Luis F Basile; José Inácio Salles; Antonio Egídio Nardi; Henning Budde; Mauricio Cagy; Roberto Piedade; Pedro Ribeiro
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-16       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.